Navigation Links
Study of Infants in Neonatal ICU Shows Low BPA Exposures Are Well Within Safe Limits
Date:2/17/2013

WASHINGTON, Feb. 18, 2013 /PRNewswire-USNewswire/ -- A study published today in Pediatrics attempted to determine whether feeding sources (breast milk or formula) or needed medical devices were the sources of BPA exposure among premature infants under medical care in a hospital intensive care unit.  The study authors, Duty, et. al, tested urine samples from infants to determine exposure levels and noted whether the infants were exposed to "high-intensity" or "low-intensity" treatment with medical devices. The following statement on the topic can be attributed to Steven G. Hentges , Ph.D., of the Polycarbonate/BPA Global Group of the American Chemistry Council.

"Balancing the benefits and risks of any medical treatment is especially important when an infant's life is at stake and this study found that exposures to BPA from the use of life-saving medical equipment on premature infants in the NICU were low and well within safe limits established by regulators. The findings are consistent with an earlier study from some of the same researchers, which noted: 'More impor­tant, our findings suggest that even premature infants have some capacity to conjugate (process) BPA.'  Combined with more extensive studies, the available evidence indicates that even premature infants have the capability to quickly metabolize and eliminate BPA from the body, similar to adults.

"The BPA exposures for all of the infants in this study are short-term, limited to the time when life-saving medical treatment is necessary, and well below government-set safe intake limits for BPA, which are conservatively set. The authors acknowledge that exposures were 'below the U.S. Environmental Protection Agency reference dose (RfD) (dose below which no adverse health effects should result from a lifetime of exposure).'

"Overall, the results of this study are consistent with U.S. Food and Drug Administration policy to maximize the benefits of medical devices with minimal risk."

www.americanchemistry.com/newsroom

The American Chemistry Council (ACC) represents the leading companies engaged in the business of chemistry. ACC members apply the science of chemistry to make innovative products and services that make people's lives better, healthier and safer. ACC is committed to improved environmental, health and safety performance through Responsible Care®, common sense advocacy designed to address major public policy issues, and health and environmental research and product testing. The business of chemistry is a $760 billion enterprise and a key element of the nation's economy. It is the largest exporting sector in the U.S., accounting for 12 percent of U.S. exports. Chemistry companies are among the largest investors in research and development. Safety and security have always been primary concerns of ACC members, and they have intensified their efforts, working closely with government agencies to improve security and to defend against any threat to the nation's critical infrastructure.


'/>"/>
SOURCE American Chemistry Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- According to a new market research report "Clinical Decision ... Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, Passive), Application - ... reach USD 1,519.2 Million by 2021 from USD 856.3 Million in 2016, ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... Dec. 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... company focused on delivering scientific and medical breakthroughs ... Chairman and Chief Executive Officer Keith Murphy ... Wednesday, December 14, 2016 at 1:00 p.m. Eastern ... not yet familiar with the Company, an informational ...
(Date:12/7/2016)... According to the latest market ... Study on Multiplex Detection Immunoassay: North America to Dominate ... detection immunoassay market is expected to witness a CAGR of ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 ... ... A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... dogs. The study was published in the prestigious Journal of Veterinary Science & ...
(Date:12/7/2016)... ... ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday Deals On ... 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , Delete® - ... on Botox® and Juvederm® just in time for the holiday party season. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors ... said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 ... drop zones. Editors can select from a variety of flip book animations. In Addition, ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “The Road ... is an everyday trial, not a one hour a week showing of hands. “The ... businessman. , Tom begins, “Perhaps you are familiar with the brass ring that you ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... individuals impacted by cerebral cavernous angiomas, was awarded a grant from the Julian ... engagement program. New Mexico has more people with cavernous angioma than anywhere in ...
Breaking Medicine News(10 mins):